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Background: Tumor hypoxia is an adverse prognostic factor which promotes cancer aggressiveness and limits its radio- and 
chemosensitivity. The aim of our study was to explore the relationship between endogenous hypoxia markers and classic 
prognostic factors, including clinical stage and the expression of ER, PR, and HER2 in primary untreated breast carcinoma. 
Methods: A retrospective immunohistochemical analysis of archived tissue blocks collected from 153 women, who 
underwent total mastectomy and lymph node dissection, included the expression of two hypoxia-related proteins: HIF-1α 
and GLUT1. Results: GLUT1 labelling index (LI) showed a positive correlation with T stage (R = 0.18, p = 0.026) and HER2 
status (R = 0.25, p = 0.002), and a negative correlation with the expression of ER (R = −0.19, p = 0.017) and PR (R = −0.17, 
p = 0.032). HIF-1α LI showed a positive correlation with ER expression (R = 0.16, p = 0.045). In the multivariate regression 
analysis, a different relationship between classic prognostic factors and the two tested hypoxia proteins was proven. Higher 
GLUT1 expression correlated with ER and PR negativity (p = 0.02 and p = 0.01, respectively) as well as with higher expression 
of HER2 (p = 0.04). HIF-1α showed no association with PR and HER2, but a positive correlation with ER (p = 0.02). Neither 
of the hypoxia proteins was associated with a tumor grade. Only one clinical feature, T stage, correlated with both of the 
hypoxia markers: positively with GLUT1 (p = 0.049) and negatively with HIF-1α (p = 0.01) expression. Conclusions: In breast 
cancer, GLUT1 expression may be considered an additional prognostic factor which correlates with an adverse status of HER2 
and hormonal receptors, and indicates a more hypoxic, radio- and chemotherapy refractory profile of carcinoma.
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Tło: Hipoksja w  guzie nowotworowym stanowi niekorzystny czynnik prognostyczny, ogranicza jego promienio- 
i chemiowrażliwość oraz promuje bardziej agresywny przebieg choroby. Przewidywanie rokowania i odpowiedzi na leczenie 
wymaga wiedzy o związku hipoksji z uznanymi czynnikami prognostycznymi. Celem badania było określenie zależności 
pomiędzy endogennymi markerami hipoksji w  pierwotnym przewodowym raku piersi a  klasycznymi czynnikami 
prognostycznymi, takimi jak stopień zaawansowania klinicznego oraz ekspresja receptorów ER, PR i HER2. Metody: 
Retrospektywna analiza immunohistochemiczna archiwizowanych bloczków tkanek pobranych od 153 kobiet, poddanych 
mastektomii i limfadenektomii pachowej, objęła ekspresję dwóch związanych z hipoksją białek: HIF-1α i GLUT1. Wyniki: 
Indeks wiązania GLUT1 (GLUT1 LI) wykazał korelację dodatnią z wielkością guza (R = 0,18, p = 0,026) i ekspresją HER2 
(R = 0,25, p = 0,002) oraz ujemną z ekspresją ER (R = −0,19, p = 0,017) i PR (R = −0,17, p = 0,032). HIF-1α LI korelował 
wyłącznie z ekspresją ER (R = 0,16, p = 0,045). W analizie wieloczynnikowej wykazano zróżnicowaną zależność pomiędzy 
klasycznymi czynnikami prognostycznymi i testowanymi markerami hipoksji. GLUT1 LI korelował negatywnie z ekspresją 
ER i PR (odpowiednio p = 0,02 i p = 0,01) oraz pozytywnie z ekspresją HER2 (p = 0,04). Nie udowodniono korelacji pomiędzy 
HIF-1α LI a ekspresją PR czy HER2, natomiast wykazano jego dodatnią zależność z ekspresją ER (p = 0,02). Żaden marker 
hipoksji nie korelował ze stopniem zróżnicowania histologicznego nowotworu. Tylko jeden kliniczny czynnik – wielkość 
guza (T) – korelował z ekspresją badanych białek: dodatnio z GLUT1 (p = 0,049), a ujemnie z HIF-1α (p = 0,01). 
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We decided to explore the link between hypoxia representa-
tive proteins: HIF-1α and GLUT1, and classic breast cancer 
prognostic factors such as clinical stage, tumor grade and 
ER, PR and HER2 expression.
MATERIAL AND METHODS
Patients
From the Department of Tumor Pathology and Pathomor-
phology at the Prof. Francis Łukaszczyk Oncology Cen-
ter, we retrieved tissue samples collected from 153 women, 
aged 25–74 years (mean age 45.14 years ± 10.76) who under-
went total mastectomy and lymph node dissection as first-
line therapy for primary invasive ductal breast carcinoma 
between 2004 and 2005. The study was approved by the 
Bioethical Board of Nicolaus Copernicus University, Col-
legium Medicum in Bydgoszcz. Written informed consent 
for participation in the study was obtained from the partici-
pants. A retrospective immunohistochemical analysis of the 
archived tissue blocks included the expression of HIF-1α and 
GLUT1 proteins. Prognostic factors, such as clinical stage, 
tumor grade as well as ER, PR and HER2 expression, were 
determined at the time of postoperative pathological diag-
nosis. The histological grade was assessed using the Elston–
Ellis system. ER and PR positivity were defined according to 
the American Society of Clinical Oncology (ASCO) recom-
mendations, and a cut-off value of 10% was used. HER2 sta-
tus was defined according to the ASCO guidelines, and cases 
showing 2+ expression were verified for HER2 amplification 
by fluorescence in situ hybridization (FISH).
There were 53 (34.64%) pT1, 90 (58.82%) pT2, 5 (3.27%) 
pT3 and 5 (3.27%) pT4 patients as well as 89 (58.17%) 
pN0, 23 (15.03%) pN1, 21 (13.72%) pN2 and 20 (13.07%) 
pN3 patients. The histological grade was determined in 
128 of 153 patients. Grade I represented 3 (2.34%) tumors, 
grade II – 98 (76.56%) and grade III – 27 (21.09%) tumors. 
There were 100 (65.36%) ER-positive, 95 (62.09%) PR-pos-
itive and 17 (11.11%) HER2-positive carcinomas (Tab. 1).
BACKGROUND
Hypoxia is a hallmark of malignant solid tumors, including breast cancer(1). It has been proven to promote cancer progression and limit treatment 
efficacy since hypoxic cells are significantly more radio- and 
chemoresistant(2). The ability to predict it is an important 
issue for offering breast cancer patients the most efficient 
treatment, as is determining so-called classic prognostic 
factors, including clinical stage, pathology (carcinoma type 
and grade) and the expression of estrogen (ER), progester-
one (PR) and epithelial B2 (ERBB2/HER2) receptors.
A central mediator of the cell’s response to hypoxic con-
ditions is a heterodimeric transcription factor, hypoxia-
inducible factor 1α (HIF-1α), which promotes the expres-
sion of genes involved in glucose metabolism, apoptosis, 
tumor angiogenesis and invasion. An HIF-1α level increases 
in many human solid tumors, and although the majority 
of clinical data confirm the protein’s negative prognos-
tic significance(3,4), there are also some contrary results(5,6). 
In breast cancer, HIF-1α has been reported to play a role 
in carcinogenesis(7) and to correlate with poor prognosis(8). 
In normoxic conditions, HIF-1α hydroxylation by prolyl 
hydroxylases (PHDs) promotes its ubiquitin-dependent 
proteosomal degradation, mainly mediated by von Hip-
pel–Lindau (VHL) E3 ubiquitin-ligase(9). Under hypoxia, 
downstream signaling of HIF-1α results from the inhibi-
tion of protein degradation (due to impaired VHL recogni-
tion by unhydroxylated prolines) and its subsequent over-
expression(10).
Glucose transporter 1 (GLUT1) is a downstream target of 
HIF-1α, which enables aerobic glycolysis in hypoxia condi-
tions by driving glucose transport in cells, thus preventing 
their death. GLUT1 overexpression has been shown in sev-
eral carcinomas in which it correlated with a higher tumor 
grade, greater invasiveness and unfavorable prognosis(11). 
In breast cancer, GLUT1 expression has been reported to 
correlate positively with tumor grade, proliferation rate and 
the risk of disease progression(12,13).
Wnioski: Ekspresja GLUT1 w raku piersi może stanowić dodatkowy czynnik prognostyczny, korelujący z niekorzystnym 
statusem receptora HER2 i  receptorów hormonalnych oraz wskazywać na bardziej hipoksyczny, oporny na radio- 
i chemioterapię, profil raka.
Słowa kluczowe: hipoksja, HIF-1α, GLUT1, czynniki prognostyczne, immunohistochemia
 
Parameter category T (n = 153) N (n = 153) G (n = 128) ER (n = 153) PR (n = 153) HER2 (n = 153)
Parameter-value 
(percentage)
1 – 53 (34.64%) 0 – 89 (58.17%) I – 3 (2.34%) (+) 100 (65.36%) (+) 95 (62.09%) (+) 17 (11.11%)
2 – 90 (58.82%) 1 – 23 (15.03%) II – 98 (76.56%) (−) 53 (34.64%) (−) 58 (37.91%) (−) 136 (88.89%)
3 – 5 (3.27%) 2 – 21 (13.72%) III – 27 (21.09%)
4 – 5 (3.27%) 3 – 20 (13.07%)
Tab. 1. The clinical-pathological data of the studied material
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Immunohistochemistry
The analysis was conducted with the EnVision method 
using the EnVision+System HRP (horseradish peroxidase, 
K 4001 and K 4002, DAKO, USA) kit and adequate mono-
clonal antibodies (monoclonal anti-HIF-1α, Chemicon 
International, USA; polyclonal anti-GLUT1, Cell Marque, 
USA). Sections (5-µm-thick) derived from 10% formalin-
fixed and paraffin-embedded tumors were placed onto 
basic adhesive slides and incubated for 2 hours at 60°C in 
a chamber thermostat. The entire pretreatment process of 
deparaffinization, rehydration and epitope retrieval was 
conducted with PTLink (a pretreatment module for tissue 
specimens) using the EnVision Flex Target Retrieval Solu-
tion, High pH (DM828). The endogenous enzymatic activ-
ity of peroxidase was inhibited with 3% hydrogen peroxide 
solution. The sections were incubated with primary anti-
bodies (1:100 for HIF-1α, 1:100 for GLUT1), and afterwards 
with an EnVision+System HRP reagent. Chromogen DAB 
(3,3-diaminobenzidine, K3468, DAKO, USA) was used to 
demonstrate the examined cellular structures. Cell nuclei 
were stained with hematoxylin (S 2020, DAKO, USA). 
As the last step, the sections were hydrated in increas-
ing ethanol dilutions, cleared in xylene and mounted in 
medium (Consul Mount, Thermo Shandon, USA).
Biomarker assessment
All slides were reviewed by two pathologists (HA, JL) using 
a light microscope with a micrometric insertion (Olym-
pus Poland). The samples chosen for evaluation came from 
hypoxic tumor regions. Viewing fields were evaluated at 
40-fold magnification under an objective lens. At least 
500 (max. 1000) breast cancer cells were counted in sev-
eral randomly selected viewing fields. A spatial correlation 
between the presence of positive staining of both markers 
was visible. The results of nuclear staining of HIF-1α and 
cytoplasmic staining of GLUT1 (Fig. 1) in cancer cells were 
shown in the form of labelling indices (LI) interpreted as 
the percentage of positively stained cells in the total num-
ber of examined breast cancer cells.
Statistics
The statistical analysis of GLUT1 and HIF-1α expression in 
relation to T and N stage, histological grade as well as ER, PR, 
and HER2 status was performed using Statistica (StatSoft, 
Inc., 2011, STATISTICA, version 10.0, www.statsoft.com) 
with the generalized regression model (GRM). In the sys-
tems that exhibited a statistical significance of the main effect, 
post-hoc tests (Tukey’s and LSD) were carried out to identify 
homogeneous groups. In all analyses, p < 0.05 was consid-
ered statistically significant. The results are shown as graphs 
in the form of average values, with 95% confidence intervals.
RESULTS
The mean labelling index of HIF-1α (LIHIF-1α) was 2.25% 
± 4.71 (range 0–35%). Based on the median LIHIF-1α value, 
we distinguished the “HIF-1α = 0%” (87/153 = 56.86%) 
and “HIF-1α  >  0%” (66/153  =  43.14%) subgroups of 
tumors. GLUT1 expression was observed in 141/153 
(92.16%) tumors. The mean labelling index of GLUT1 
(LIGLUT1) was 48.49% ± 32.71 (range 0–100%). Based on the 
median LIGLUT1 value, we divided GLUT1-positive tumors 
into GLUT1 < 50% (75/153 = 49.02%) and GLUT > 50% 
(78/153 = 50.98%) subgroups.
Associations between the expression of the hypoxia-related 
proteins and classic prognostic factors, utilizing the Spear-
man test, are summarized in Tab. 2. In this analysis, the 
GLUT1 labelling index showed a positive correlation with 
T stage (R = 0.18, p = 0.026) as well as HER2 status (R = 0.25, 
p = 0.002), and a negative correlation with the expression of 
both hormonal receptors: ER (R = −0.19, p = 0.017) and PR 
(R = −0.17, p = 0.032). HIF-1α labelling index showed only 
one significant relationship which was a positive correlation 
with ER expression (R = 0.16, p = 0.045).
In the multivariate regression analysis, a different rela-
tionship between clinical-pathological prognostic factors 
and the two tested hypoxia proteins, HIF-1α and GLUT1, 
was also proven. The results are summarized in Fig. 2 and 
Fig. 3. A higher GLUT1 expression correlated with ER and 
PR negativity (p = 0.02 and p = 0.01, respectively) and with 
a higher expression of HER2 (p = 0.04) (Fig. 2). HIF-1α 
showed no correlation with PR and HER2 and, in con-
trast to GLUT1, a higher expression in ER-positive tumors 
(p = 0.02) (Fig. 2). None of the hypoxia proteins was associ-
ated with a tumor grade (Fig. 3). Only one clinical feature, 
T stage, correlated significantly, but mutually inversely, with 
both of the hypoxia markers (Fig. 3). We observed a posi-
tive correlation with GLUT1 expression (p = 0.049), which 
was highest for T4 tumors, and a negative correlation with 
HIF-1α expression (p = 0.01), which was highest for T1 
tumors.
Fig. 1.  HIF-1α nuclear staining and GLUT1 cytoplasmic stain-
ing in breast cancer cells of two different patients. Orig-
inal magn. 400×
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DISCUSSION
Based on the literature and our previous results on the rela-
tionship of hypoxia with classic prognostic factors in pros-
tate cancer(14) and its meaning in carcinogenesis(15), we also 
expected to find a correlation between the approved clin-
ical-pathological prognostic factors and hypoxia-related 
proteins in breast carcinoma.
We found an association between GLUT1 expression and 
other tumor biological markers, including a negative cor-
relation with the recognized favorable prognostic factors, 
such as ER and PR expression, and a positive correlation 
with an unfavorable prognostic factor, i.e. HER2 overex-
pression. In contrast to GLUT1, HIF-1α did not correlate 
with either PR or HER2 expression but correlated pos-
itively with ER expression. Since studies conducted on 
tissues and cell lines have indicated a close dependence 
of GLUT expression on HIF-1α activation(10,11), we rather 
expected consistent results for both hypoxia markers. 
When discussing a differential relationship of GLUT1 
and HIF-1α with standard receptor prognostic factors, 
we took into consideration relatively low labelling indi-
ces of HIF-1α obtained in our study with a high propor-
tion of LIHIF-1α = 0% (about 57%) and low mean LIHIF-1α 
reaching 2.25%, a factor which might have influenced the 
results of the statistical analysis. One should also allow 
for the fact that transient stabilization and short half-
life of endogenous HIF proteins may limit their useful-
ness in detection of tumor hypoxic response(16). Finally, 
in cancer cells, the expression of both proteins can be 
up-regulated not only by hypoxia. GLUT1 expression 
also depends on growth factors(17), suppressor genes(18), 
oncogenes(19,20) and the PI3K/AKT/ mTOR molecular 
pathway(21), and may not be even connected with HIF-1α 
activity(20). In contrast, HIF-1α expression can be up-reg-
ulated by activation of the PI3K and ERK1/2 intracellular 
pathways as well as due to the loss of tumor suppressor 
genes such as PTEN and p53(22,23). Additionally, HIF-1α 
proteosomal degradation may be the result of the expres-
sion of either von Hippel–Lindau E3 ubiquitin-ligase(9) or 
Sharp-1, a basic helix–loop–helix transcription factor(24). 
Molecular studies by Surazynski et al. might be to some 
extent a confirmation of our findings on the relation-
ship between HIF-1α and ER(25). The authors suggested 
that α-estrogen receptor up-regulates the activity of pro-
lidase, which in turn contributes to an increase in HIF-1α 
nuclear localization.
The significance of hypoxia proteins in breast cancer has 
been also explored in several clinical studies. Koda et al. 
showed, similarly to our results, a negative correlation 
between ER expression and GLUT1 in primary breast 
cancers and lymph node metastasis, which they did not 
prove for HIF-1α(26). Choi et al. reported, in turn, that the 
expression of both GLUT1 and HIF-1α correlated with ER 
and PR negativity. HIF-1α was associated with HER2 over-
expression, while high GLUT1 expression was correlated 
with a triple (ER, PR, HER2) negative subtype of breast 
cancer(27).
Hypoxia increases with tumor growth, the consequence 
of which should be a  link between hypoxia markers 
Parameter LI GLUT1 < 50%N = 75 (49.02%)
LI GLUT1 > 50%
N = 78 (50.98%) p/R
LI HIF-1α = 0
N = 87 (56.86%)
LI HIF-1α < 0
N = 66 (43.14%) p/R
T stage
T1
T2
T3
T4
32 (20.92)
40 (26.14)
2 (1.31)
1(0.65)
21 (13.73)
50 (32.68)
3 (1.96)
4 (2.61)
0.026/0.18
27 (17.65)
54 (35.29)
3 (1.96)
3 (1.96)
26 (16.99)
36 (23.53)
2 (1.31)
2 (1.31)
NS
N stage
N0
N1
N2
N3
45 (29.41)
14 (9.15)
6 (3.92)
10 (6.54)
44 (28.76)
9 (5.88)
15 (9.80)
10 (6.54)
NS
49 (32.03)
15 (9.80)
15 (9.80)
8 (5.23)
40 (26.14)
8 (5.23)
6 (3.92)
12 (7.84)
NS
ER PositiveNegative
56 (36.60)
19 (12.42)
44 (28.76)
34 (22.22) 0.017/−0.19
51 (33.33)
36 (23.53)
49 (32.03)
17 (11.11) 0.045/0.16
PR PositiveNegative
53 (34.64)
22 (14.38)
42 (27.45)
36 (23.53) 0.032/−0.17
49 (32.03)
38 (24.84)
46 (30.07)
20 (13.07) NS
HER2
(−)
(+)
(++)
(+++)
30 (19.61)
35 (22.88)
6 (3.92)
4 (2.61)
20 (13.07)
29 (18.95)
16 (10.46)
13 (8.50)
0.002/0.25
32 (20.92)
29 (18.95)
14 (9.15)
12 (7.84)
18 (11.76)
35 (22.88)
8 (5.23)
5 (3.27)
NS
Grade III
III
N = 64 (50%)
2 (1.56)
50 (39.06)
12 (9.38)
N = 64 (50%)
1 (0.78)
48 (37.50)
15 (11.72)
NS
N = 74 (57.81%)
2 (1.56)
57 (44.53)
15 (11.72)
N = 54 (42.19%)
1 (0.78)
41 (32.03)
12 (9.38)
NS
Tab. 2.  Associations between the expression of hypoxia-related proteins and classic prognostic factors. The correlation between the pairs of 
parameters is expressed with the Spearman’s correlation coefficient (R)
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and a tumor stage. In our study, such a correlation was 
observed only for GLUT1, whose expression (understood 
as hypoxia level) was proportional to the tumor size. 
We did not notice the same effect for HIF-1α, for which 
the highest expression was present in the smallest tumors. 
Having analyzed this, we allowed for a heterogeneous 
distribution of T stage in the studied group which was 
dominated by T1 and T2 groups (94%). The systemic 
review of studies on hypoxia marker expression in breast 
cancer by Adams et al. revealed no association between 
GLUT1 and tumor size(28). However, such a correlation has 
been reported for other carcinomas(29,30).
Fig. 2.  Relationship between pathological prognostic factors: ER, PR as well as HER2 and hypoxia-related proteins: HIF-1α and GLUT1 
(average values with 95% confidence intervals)
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We did not confirm any relationship with a histological 
grade either for GLUT1 or for HIF-1α, which is contrary to 
some other observations(7,28) and undoubtedly influenced by 
the dominance of grade II tumors that accounted for about 
80% of the whole studied group.
CONCLUSIONS
The results of our study suggest that GLUT1 might be 
a valuable prognostic factor in breast cancer patients. 
As an indicator of a tumor hypoxic profile, it correlates 
with adverse hormonal and HER2 receptor status as well 
Fig. 3.  Relationship between clinical prognostic factors: T stage, N stage as well as tumor grade and hypoxia-related proteins: HIF-1α and 
GLUT1 (average values with 95% confidence intervals)
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as tumor stage. A differential link of GLUT1 and HIF-1α 
with the classic prognostic factors might to some extent 
reflect a methodological advantage of glucose transporter 
testing, but may also provoke further studies on a very 
complicated network of molecular pathways in which both 
hypoxia markers are engaged. Since one rather looks for 
straightforward tools to be used for classifying patients 
into prognostic groups in clinical practice, GLUT1 seems 
to be a promising answer.
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